KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Current Assets (2016 - 2026)

Pacira BioSciences has reported Current Assets over the past 17 years, most recently at $515.0 million for Q1 2026.

  • For Q1 2026, Current Assets fell 32.24% year-over-year to $515.0 million; the TTM value through Mar 2026 reached $515.0 million, down 32.24%, while the annual FY2025 figure was $548.0 million, 26.46% down from the prior year.
  • Current Assets for Q1 2026 was $515.0 million at Pacira BioSciences, down from $548.0 million in the prior quarter.
  • Over five years, Current Assets peaked at $760.0 million in Q1 2025 and troughed at $376.1 million in Q1 2023.
  • A 5-year average of $572.3 million and a median of $543.1 million in 2024 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: tumbled 43.61% in 2023 and later skyrocketed 54.27% in 2024.
  • Year by year, Current Assets stood at $498.3 million in 2022, then increased by 2.34% to $510.0 million in 2023, then surged by 46.11% to $745.1 million in 2024, then fell by 26.46% to $548.0 million in 2025, then dropped by 6.02% to $515.0 million in 2026.
  • Business Quant data shows Current Assets for PCRX at $515.0 million in Q1 2026, $548.0 million in Q4 2025, and $562.8 million in Q3 2025.